References
- Roberts KG, Reshmi SC, Harvey RC, Chen IM, Patel K, Stonerock E, et al. Genomic and outcome analyses of Ph-like ALL in NCI standard-risk patients: a report from the children’s oncology group. Blood 2018; 132: 815-24. doi: 10.1182/blood-2018-04-841676
- Hunger SP, Lu X, Devidas M, Camitta BM, Gaynon PS, Winick NJ, et al. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children’s oncology group. J Clin Oncol 2012; 30: 1663-9. doi: 10.1200/JCO.2011.37.8018
- Ward E, DeSantis C, Robbins A, Kohler B, Jemal A. Childhood and adolescent cancer statistics, 2014. CA Cancer J Clin 2014; 64: 83-103. doi: 10.3322/caac.21219
- Einsiedel HG, Von Stackelberg A, Hartmann R, Fengler R, Schrappe M, Janka-Schaub G, et al. Long-term outcome in children with relapsed ALL by risk-stratified salvage therapy: results of trial Acute Lymphoblastic Leukemia-Relapse Study of the Berlin-Frankfurt-Münster Group 87. J Clin Oncol 2005; 23: 7942-50. doi: 10.1200/JCO.2005.01.1031
- Olsson L, Ivanov Öfverholm II, Norén-Nyström U, Zachariadis V, Nordlund J, Sjögren H, et al. The clinical impact of IKZF1 deletions in paediatric B-cell precursor acute lymphoblastic leukaemia is independent of minimal residual disease stratification in Nordic Society for Paediatric Haematology and Oncology treatment protocols used between 1992 aand 1993. Br J Haematol 2015; 170: 847-58. doi: 10.1111/bjh.13514
- Dörge P, Meissner B, Zimmermann M, Möricke A, Schrauder A, Bouquin JP, et al. IKZF1 deletion is an independent predictor of outcome in pediatric acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol. Haematologica 2013; 98: 428-32. doi: 10.3324/haematol.2011.056135
- Asai D, Imamura T, Suenobu S, Saito A, Hasegawa D, Deguchi T, et al. IKZF 1 deletion is associated with a poor outcome in pediatric B-cell precursor acute lymphoblastic leukemia in Japan. Cancer Med 2013; 2: 412-9. doi: 10.1002/cam4.87
- Kuiper RP, Waanders E, Van Der Velden VHJ, Van Reijmersdal SV, Venkatachalam R, Scheijen B, et al. IKZF1 deletions predict relapse in uniformly treated pediatric precursor B-ALL. Leukemia 2010; 24: 1258-64. doi: 10.1038/leu.2010.87
- Mullighan CG, Su X, Zhang J, Radtke I, Phillips LAA, Miller CB, et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med 2009; 360: 470-80. doi: 10.1056/NEJMoa0808253
- Georgopoulos K, Bigby M, Wang JH, Molnar A, Wu P, Winandy S, et al. The ikaros gene is required for the development of all lymphoid lineages. Cell 1994; 79: 143-56. doi: 10.1016/0092-8674(94)90407-3
- Molnar A, Wu P, Largespada DA, Vortkamp A, Scherer S, Copeland NG, et al. The Ikaros gene encodes a family of lymphocyte-restricted zinc finger DNA binding proteins, highly conserved in human and mouse. J Immunol 1996; 156: 585-92. PMID: 8543809
- Yang YL, Hung CC, Chen JS, Lin KH, Jou ST, Hsiao CC, et al. IKZF1 deletions predict a poor prognosis in children with B-cell progenitor acute lymphoblastic leukemia: a multicenter analysis in Taiwan. Cancer Sci 2011; 102: 1874-81. doi: 10.1111/j.1349-7006.2011.02031.x
- Van Der Veer A, Waanders E, Pieters R, Willemse ME, Van Reijmersdal S V., Russell LJ, et al. Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL. Blood 2013; 122: 2622-9. doi: 10.1182/blood-2012-10-462358
- Moorman A V., Enshaei A, Schwab C, Wade R, Chilton L, Elliott A, et al. A novel integrated cytogenetic and genomic classification refines risk stratification in pediatric acute lymphoblastic leukemia. Blood 2014; 124: 1434-44. doi: 10.1182/blood-2014-03-562918
- Mullighan CG, Miller CB, Radtke I, Phillips LA, Dalton J, Ma J, et al. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature 2008; 453: 110-14. doi: 10.1038/nature06866
- Van Der Veer A, Zaliova M, Mottadelli F, De Lorenzo P, Te Kronnie G, Harrison CJ, et al. IKZF1 status as a prognostic feature in BCR-ABL1-positive childhood ALL. Blood 2014; 123: 1691-8. doi: 10.1182/blood-2013-06-509794
- Roberts KG. The biology of Philadelphia chromosome-like ALL. Best Pract Res Clin Haematol 2017; 30: 212-21. doi: 10.1016/j.beha.2017.07.003
- Boer JM, Van Der Veer A, Rizopoulos D, Fiocco M, Sonneveld E, De Groot-Kruseman HA, et al. Prognostic value of rare IKZF1 deletion in childhood B-cell precursor acute lymphoblastic leukemia: an international collaborative study. Leukemia 2016; 30: 32-38. doi: 10.1038/leu.2015.199
- Steeghs EMP, Boer JM, Hoogkamer AQ, Boeree A, de Haas V, de Groot-Kruseman HA, et al. Copy number alterations in B-cell development genes, drug resistance, and clinical outcome in pediatric B-cell precursor acute lymphoblastic leukemia. Sci Rep 2019; 9: 1-11. doi: 10.1038/s41598-019-41078-4
- Stanulla M, Cavé H, Moorman A V. IKZF1 deletions in pediatric acute lymphoblastic leukemia: still a poor prognostic marker? Blood 2020; 135: 252-60. doi: 10.1182/blood.2019000813
- Stanulla M, Dagdan E, Zaliova M, Möricke A, Palmi C, Cazzaniga G, et al. IKZF1 plus defines a new minimal residual disease-dependent very-poor prognostic profile in pediatric b-cell precursor acute lymphoblastic leukemia. J Clin Oncol 2018; 36: 1240-9. doi: 10.1200/JCO.2017.74.3617
- Gu Z, Churchman ML, Roberts KG, Moore I, Zhou X, Nakitandwe J, et al. PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia. Nat Genet 2019; 51: 296-307. doi: 10.1038/s41588-018-0315-5
- Schwab C, Nebral K, Chilton L, Leschi C, Waanders E, Boer JM, et al. Intragenic amplification of PAX5: a novel subgroup in B-cell precursor acute lymphoblastic leukemia? Blood Adv 2017; 1: 1473-7. doi: 10.1182/bloodadvances.2017006734
- Zhang W, Kuang P, Liu T. Prognostic significance of CDKN2A/B deletions in acute lymphoblastic leukaemia: a meta-analysis. Ann Med 2019; 51: 28-40. doi: 10.1080/07853890.2018.1564359
- Carrasco Salas P, Fernández L, Vela M, Bueno D, González B, Valentín J, et al. The role of CDKN2A/B deletions in pediatric acute lymphoblastic leukemia. Pediatr Hematol Oncol 2016; 33: 415-22. doi: 10.1080/08880018.2016.1251518
- Zhang W, Kuang P, Liu T. Prognostic significance of CDKN2A/B deletions in acute lymphoblastic leukaemia: a meta-analysis. Ann Med 2019; 51: 28-40. doi: 10.1080/07853890.2018.1564359
- Yamashita Y, Shimada A, Yamada T, Yamaji K, Hori T, Tsurusawa M, et al. IKZF1 and CRLF2 gene alterations correlate with poor prognosis in japanese BCR-ABL1-negative high-risk B-cell precursor acute. Pediatr Blood Cancer 2013; 60: 1587-92. doi: 10.1002/pbc
- Palmi C, Valsecchi MG, Longinotti G, Silvestri D, Carrino V, Conter V, et al. What is the relevance of Ikaros gene deletions as a prognostic marker in pediatric Philadelphia-negative B-cell precursor acute lymphoblastic leukemia? Haematologica 2013; 98: 1226-31. doi: 10.3324/haematol.2012.075432
- Clappier E, Grardel N, Bakkus M, Rapion J, De Moerloose B, Kastner P, et al. IKZF1 deletion is an independent prognostic marker in childhood B-cell precursor acute lymphoblastic leukemia, and distinguishes patients benefiting from pulses during maintenance therapy: results of the EORTC Children’s Leukemia Group study 58951. Leukemia 2015; 29: 2154-61. doi: 10.1038/leu.2015.134
- Vrooman LM, Blonquist TM, Harris MH, Stevenson KE, Place AE, Hunt SK, et al. Refining risk classification in childhood b acute lymphoblastic leukemia: results of DFCI ALL consortium protocol 05-001. Blood Adv 2018; 2: 144958. doi: 10.1182/bloodadvances.2018016584
- Öfverholm I, Tran AN, Heyman M, Zachariadis V, Nordenskjöld M, Nordgren A, et al. Impact of IKZF1 deletions and PAX5 amplifications in pediatric B-cell precursor ALL treated according to NOPHO protocols. Leukemia 2013; 27: 1936-9. doi: 10.1038/leu.2013.92
- Schwab CJ, Jones LR, Morrison H, Ryan SL, Yigittop H, Schouten JP, et al. Evaluation of multiplex ligation-dependent probe amplification as a method for the detection of copy number abnormalities in B-cell precursor acute lymphoblastic leukemia. Genes Chromosom Cancer 2010; 49: 1104-13. doi: 10.1002/gcc
- Schwab CJ, Chilton L, Morrison H, Jones L, Al-Shehhi H, Erhorn A, et al. Genes commonly deleted in childhood B-cell precursor acute lymphoblastic leukemia: association with cytogenetics and clinical features. Haematologica 2013; 98: 1081-8. doi: 10.3324/haematol.2013.085175
- Mullighan CG, Goorha S, Radtke I, Miller CB, Coustan-Smith E, Dalton JD, et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 2007; 446: 758-64. doi: 10.1038/nature05690
- Kim M, Choi JE, She CJ, Hwang SM, Shin HY, Ahn HS, et al. PAX5 deletion is common and concurrently occurs with CDKN2A deletion in B-lineage acute lymphoblastic leukemia. Blood Cells, Mol Dis 2011; 47: 62-6. doi: 10.1016/j.bcmd.2011.04.003
- Kawamata N, Ogawa S, Zimmermann M, Sanada M, Hemminki K, Yamatomo G, et al. Rearrangement and deletion of the PAX5 gene in pediatric acute B-cell lineage lymphoblastic leukemia. Blood 2007; 110: 981. doi: 10.1182/blood.V110.11.981.981
- Kim M, Choi JE, She CJ, Hwang SM, Shin HY, Ahn HS, et al. PAX5 deletion is common and concurrently occurs with CDKN2A deletion in B-lineage acute lymphoblastic leukemia. Blood Cells, Mol Dis 2011; 47: 62-6. doi: 10.1016/j.bcmd.2011.04.003
- Paulsson K, Johansson B. High Hyperdiploid childhood acute lymphoblastic leukemia. Genes Chromosom Cancer 2009; 48: 637-60. doi: 10.1002/gcc.20671
- Palmi C, Vendramini E, Silvestri D, Longinotti G, Frison D, Cario G, et al. Poor prognosis for P2RY8-CRLF2 fusion but not for CRLF2 over-expression in children with intermediate risk B-cell precursor acute lymphoblastic leukemia. Leukemia 2012; 26: 2245-53. doi: 10.1038/leu.2012.101